Previous Article | Next Article ![]()
Journal of Virology, May 2004, p. 4599-4608, Vol. 78, No. 9
0022-538X/04/$08.00+0 DOI: 10.1128/JVI.78.9.4599-4608.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Susumu Antoku,
and Sandra K. Weller*
Department of Molecular, Microbial, and Structural Biology, University of Connecticut Health Center, Farmington, Connecticut 06030-3205
Received 26 November 2003/ Accepted 23 December 2003
|
|
|---|
|
|
|---|
The UL12 protein interacts with the HSV-1 single-stranded DNA binding protein, ICP8 (34, 36). Recently, it was shown that these two proteins work together to mediate a strand exchange reaction in vitro, demonstrating that the proteins have activities analogous to that of the Red recombinase from bacteriophage lambda (26). The Red recombinase is composed of two components, the 5'-3' exonuclease Red alpha and the single-stranded DNA binding protein Red beta, which acts as a synaptase. The UL12 gene shows homology with lambda red
, the gene for the exonuclease partner of the two-part recombinase. In fact, every member of the herpesvirus family studied to date encodes a nuclease with homology to the red
product (R. S. Myers and K. E. Rudd, presented at the 1998 Miami Nature Biotechnology Winter Symposium, 1998). The conservation of these sequences from viruses of plants, animals, and bacteria (Myers and Rudd, presented at the 1998 Miami Nature Biotechnology Winter Symposium) suggests that recombination may play an important role in the biology of double-stranded DNA viruses with linear genomes. Our finding that the UL12 protein has in vitro recombinase activity like that of the Red recombinase is consistent with this hypothesis. Since HSV-1 DNA replication is associated with a high degree of homologous recombination (1, 8, 9, 28, 35) and replication intermediates exhibit a complex, possibly branched structure (29), we and others have proposed that recombination-dependent replication is important in HSV (reviewed in reference 38). The observation that UL12 and ICP8 can carry out a strand exchange reaction supports the notion that UL12 has a role in mediating homologous recombination. The exonuclease activity is required for the recombinase activity of UL12, as a mutant lacking exonuclease activity was shown to be unable to mediate strand exchange (26).
The UL12 gene is encoded by a 2.3-kb mRNA, and embedded within this gene is a subgenic 1.9-kb mRNA encoding an N-terminally truncated version of UL12, designated UL12.5 (6, 7, 24). Like UL12, UL12.5 is expressed with early or ß kinetics, but the 1.9-kb transcript is expressed threefold less efficiently than the 2.3-kb transcript for full-length UL12 (7). The UL12.5 protein is found in much smaller amounts than UL12 (4). Comparisons of UL12 and UL12.5 activities have shown that the endo- and exonuclease activities of UL12.5 are similar to those of UL12 (4, 11). However, despite the similarity of activity, UL12.5 cannot efficiently complement the AN-1 virus when UL12.5 is introduced into cells via the transfection of expression plasmids (11, 24). Furthermore, a frameshift mutation, ANF-1, consisting of two nucleotides inserted 14 nucleotides downstream of the translational start site of full-length UL12, was generated, and it expresses UL12.5 at wild-type levels but is null for the full-length protein (24). ANF-1 has a phenotype identical to that of the null AN-1 virus, despite the fact that UL12.5 is present. The inability of UL12.5 to complement a UL12 null mutant thus poses a dilemma and suggests that an essential function of UL12 lies within the first 126 residues.
To further characterize essential functions in this genetic locus, we set out to compare in greater detail the biochemical activities of these two proteins. We constructed a recombinant baculovirus for the expression of UL12.5, and we purified UL12.5 in soluble form. We confirmed the earlier studies by finding that UL12.5 possesses nuclease activity similar to that of UL12. In addition, we found that UL12.5 could be coimmunoprecipitated with ICP8 as efficiently as UL12 and could also mediate strand exchange activity with ICP8. These results did not explain why UL12.5 was not able to efficiently complement AN-1. The answer to this apparent dilemma came with the observation that in transfected cells UL12.5 was cytoplasmic, while UL12 was strongly localized to the nucleus. Furthermore, a green fluorescent protein (GFP) fusion of the N-terminal 126 residues of UL12 localized to the nucleus, indicating that this domain contains a nuclear localization signal (NLS). The cytoplasmic localization of UL12.5 is most likely the reason for its inability to complement the UL12 null virus.
|
|
|---|
DNA.
M13mp18 replicative form was purified from infected Escherichia coli UT481 [
(lac-pro) hsdS(rm) lacIq lacZ] cells using the Qiagen (Valencia, Calif.) maxiplasmid kit. M13mp18 single-stranded DNA was purified from M13 phage-infected UT481 cells according to standard protocols (21). DNA fragments were purified from agarose gels using the GeneClean spin kit (Bio-101, La Jolla, Calif.).
Materials.
Restriction endonucleases and other DNA-modifying enzymes were purchased from New England Biolabs (Beverly, Mass.) or from Invitrogen. DNA primers were from Invitrogen.
Plasmids. For expression in mammalian cells, the vector pSAK was used. This plasmid was derived from the plasmid pEGFP-C1 (Clontech-BD Biosciences, San Jose, Calif.), which expresses enhanced GFP (EGFP) from the cytomegalovirus (CMV) immediate-early promoter. The coding region for EGFP was deleted from this plasmid by cutting it with NheI and BglII. The ends were blunted with the Klenow fragment of DNA polymerase I and religated, creating the pSAK vector. The vector was used for expression of UL12 and UL12.5 in Vero cells. Vectors pSAKUL12.5 and pSAKUL12/12.5 were generated by PCR of the wild-type UL12 gene found on the previously described plasmid pUC119-AK (24). The plasmid construct expressing only UL12, and not UL12.5, called pSAKUL12, was generated by PCR of the plasmid pF1'-CMV-AK(M127F) (22). The PCR primers used in the preparation of these constructs were as follows: forward primer for UL12 constructs, 5' GGAATTCCGCCACCATGGAGTCCACGGGAGGCCC; forward primer for UL12.5, 5' GGAATTCCGCCACCATGTGGTCGGCGTCGGTGAT; reverse primer for UL12 and UL12.5 constructs, 5' GGGGTACCTCAGCGAGACGACCTCCCCG. The restriction sites for EcoRI and KpnI are italicized, and the Kozak consensus sequence for initiation (19) is shown in boldface. The PCR-generated fragments were cloned into pSAK at the EcoRI and KpnI sites. The plasmids for expression of UL12, UL12.5, or the N terminus of UL12 fused to EGFP or to a hemagglutinin (HA) tag were constructed by first cloning full-length gene fragments with no stop codons (fusion ready) into pSAK. The forward primers for PCR were the same as those listed above, and the reverse primers were as follows: for full-length UL12 and UL12.5, 5' GTGGATCCTCAGGTACCGCGAGACGACCTCCCCGTCG; for the N terminus of UL12, 5' GGGGTACCAGAATCAAGGTCCGGGGAGTC, with the KpnI sites italicized. These PCR fragments were cloned into pSAK at the EcoRI and KpnI sites. HA tags were fused to the C termini of the various constructs by cutting the vectors with KpnI and BamHI and ligating annealed oligonucleotides encoding the tag and possessing the overhangs necessary for annealing to KpnI and BamHI. The oligonucleotides used were 5' CTACCCATACGATGTTCCGGATTACGCTTGAG and 5' GATCCTCAAGCGTAATCCGGAACATCGTATGGGTAGGTAC, with the annealing sequences for BamHI and KpnI italicized. To add EGFP to the C termini of UL12, UL12.5, or the N-terminal domain of UL12, a fragment encoding EGFP was generated by PCR using pEGFP-C1 as a template. The primers used were as follows: forward primer, 5' CGGGGTACCGTGAGCAAGGGCGAGGAGCTG; reverse primer, 5' CGCGGATCCTCACTTGTACAGCTCGTCCATGC, with the KpnI and BamHI sites underlined. The GFP-containing fragment was cloned into the fusion-ready vectors at the KpnI and BamHI sites. The resulting clones had EGFP fused in frame to the C termini of UL12 and UL12.5 or the N-terminal domain of UL12.
Antibodies. The anti-UL12 BWp12 antibody was a generous gift from Joel Bronstein and Peter Weber (3, 24). The polyclonal anti-ICP8 antibody 3-83 was kindly provided by David Knipe (17). The monoclonal anti-ICP8 antibody 39-S was generously provided by M. Zweig (31). Goat anti-rabbit conjugated to Alexa Fluor 488 was from Molecular Probes (Eugene, Oreg.). The anti-HA antibody sc-805 was from Santa Cruz Biotechnology (Santa Cruz, Calif.).
Protein expression and purification. For preparation of a recombinant baculovirus expressing UL12.5, the Bac-to-Bac system (Invitrogen) was used. The UL12.5 gene was generated by PCR using pUC119AK as the template with the following primers: forward primer, 5' CGGGATCCGCCACCATGTGGTCGGCGTCGGTGATCCCC; reverse primer, 5' GGAATTCTCAGCGAGACGACCTCCC. The restriction sites for BamHI and EcoRI are italicized, and the Kozak consensus sequence for initiation (19) is shown in boldface. The PCR-generated fragment was digested with EcoRI and BamHI and cloned into the pFastBac vector at those sites. The resulting plasmid, pFastBacUL12.5L, was confirmed by DNA sequencing (Molecular Core, University of Connecticut Health Center). The transfer of the UL12.5 construct to the baculovirus bacmid by homologous recombination was done according to the manufacturer's protocols. The resulting baculovirus was named AcUL12.5. The UL12-expressing baculovirus AcAN was kindly provided by Fred L. Homa (Pharmacia & Upjohn, Kalamazoo, Mich.). The ICP8-expressing baculovirus AcUL29 was a generous gift from Nigel D. Stow (32).
The UL12.5 protein was purified according to the protocol that had been used for the purification of UL12, with minor modifications (10). In order to be able to compare the activities of the two proteins, both UL12 and UL12.5 were purified, using the same protocol. The UL12 protein, prepared by Josh Goldstein and described previously (10), was also used as a control. The new UL12 preparations had the same exonuclease activity as the UL12 protein described previously (reference 10 and data not shown). Briefly, Sf9 insect cells were grown in suspension and infected with recombinant baculovirus. The infected cells were collected after 50 h of incubation at 27°C. The cells were pelleted, washed with phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4 · 7H2O, 1.4 mM KH2PO4, pH 7.3), repelleted, and frozen at 80°C. Cells (
5 g) were thawed and resuspended in 40 ml of cold buffer A (10 mM Tris-Cl, pH 7.5, 1 mM MgCl2, 80 mM KCl, 0.5 mM dithiothreitol [DTT], 0.2% NP-40). Protease inhibitors were added at the following concentrations: 13 µg of aprotinin/ml, 7 µg of leupeptin/ml, 7 µg of pepstatin A/ml, and 1 mM phenylmethylsulfonyl fluoride (PMSF). After 10 min of swelling on ice, the cells were disrupted by 10 strokes of a Dounce homogenizer. The nuclei were pelleted, and the supernatant was clarified by centrifugation at 100,000 x g in an SW28 rotor. The extract was brought to 20% saturation with ammonium sulfate, and the precipitate was removed by centrifugation. The UL12 or UL12.5 protein was then precipitated from the supernatant by bringing the ammonium sulfate saturation up to 55%. The precipitate was resuspended in 5 ml of buffer B (20 mM potassium phosphate, pH 8.0, 20% glycerol, 5 mM ß-mercaptoethanol) and dialyzed overnight against buffer B. The dialysate was clarified by centrifugation and loaded on a 20-ml HiLoad 16/10 SP-Sepharose column (Pharmacia, Piscataway, N.J.) that had been equilibrated with buffer B. The proteins were eluted using a gradient from 20 to 500 mM potassium phosphate. UL12 and UL12.5 typically eluted at 0.1 to 0.2 M salt. Fractions containing the desired protein were pooled, concentrated using Biomax 50K concentrators (Millipore, Bedford, Mass.), and loaded onto a Superose 12 gel filtration column (Pharmacia) that had been equilibrated with buffer C (20 mM potassium phosphate, pH 8.0, 10% glycerol, 5 mM ß-mercaptoethanol). Fractions were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The fractions used for biochemical analysis were determined to be >90% pure, as measured by densitometry of Coomassie blue-stained gels. Protein concentrations were determined by the Bradford method (2) using the reagent prepared by Bio-Rad (Hercules, Calif.).
Immunoprecipitation. Sf9 insect cells (9 x 106) were plated in 100-mm-diameter dishes 3 h prior to infection. The cells were infected with the recombinant baculoviruses and harvested 50 h later by scraping the cells from the dish. The cells were centrifuged at 2,000 x g and washed with PBS. The cell pellets were lysed in 1.2 ml of modified RIPA buffer (25 mM Tris-Cl, pH 8.0, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate, 10 mM ß-glycerophosphate, 1 mM sodium vanadate, 1 mM phenylmethylsulfonyl fluoride, 20 µg of aprotinin/ml), and were disrupted by sonication with a microtip (Misonix, Farmingdale, N.Y.) for 30 s. The insoluble fraction was removed by centrifugation at 100,000 x g for 30 min at 4°C. The protein concentrations of the lysates were determined by the Bradford method (2) using the reagent prepared by Bio-Rad. The lysates were analyzed by SDS-PAGE and immunoblotting (21).
For immunoprecipitation experiments, 150 µl of insect cell lysate (normalized for protein concentration so that the same amount of total protein was present in each sample) was combined with 150 µl of modified RIPA buffer containing 1 mM phenylmethylsulfonyl fluoride and 20 µg of aprotinin/ml. Each reaction mixture was incubated with 25 µl of mouse monoclonal anti-ICP8 antibody (39-S) for 1.5 h at 4°C. To precipitate the protein-antibody complexes, 15 µl of protein A-G-Sepharose (Amersham Pharmacia Biotech, Piscataway, N.J.) was added, and incubation was continued for 1 h. Immune complexes were pelleted by centrifugation at 14,000 x g for 10 s. The volume of each sample was reduced to 100 µl by aspiration, and each sample was washed three times in RIPA buffer. After the final wash, the volume was reduced to 15 µl, and 5 µl of 4x gel loading buffer was added. The samples were analyzed by SDS-PAGE and immunoblotting using the anti-UL12 BWp12 antibody (3, 24) and the 3-83 anti-ICP8 antibody (17). The immunoblots were developed using the ECL system (Amersham).
Transfection of Vero cells. For transfection of Vero cells, 106 cells were plated in 35-mm-diameter six-well dishes 1 day prior to transfection. The cells were transfected with a total of 1 µg of plasmid DNA using Lipofectamine PLUS (Invitrogen). For experiments involving titration of the amount of protein-expressing vector, the empty parent vector was included in the transfection so that the total amount of DNA remained 1 µg. The cells were harvested 24 h posttransfection, washed in PBS, and lysed in modified RIPA buffer. The crude cell lysates were centrifuged at 14,000 x g and 4°C and used for SDS-PAGE and immunoblot analyses.
Strand exchange assay. The reaction was carried out in a final volume of 20 µl as described previously (26). Each reaction mixture consisted of 100 ng of circular single-stranded M13mp18 DNA (2 nM), 100 ng of linear (PstI-cut) double-stranded M13mp18 (1 nM), 18.8 ng of UL12 (13.9 nM) or 15.3 ng of UL12.5 (13.9 nM), 4.5 µg of ICP8 (1.75 µM), 20 mM Tris-Cl (pH 7.5), 40 mM NaCl, 1 mM MgCl2, and 1 mM DTT. The reaction mixture was incubated at 37°C, and the reaction was stopped by adding 5 µl of 5x stop buffer (50% glycerol, 50 mM EDTA, 1% SDS, 0.2% bromphenol blue). Samples were electrophoresed on a 1% agarose gel with 0.7 µg of ethidium bromide/ml in TAE buffer (0.04 M Tris-acetate, 0.001 M EDTA). Adobe Photoshop (version 6.0) and Adobe Illustrator (version 10.0) were used in the preparation of figures.
Exonuclease assay. Total unlabeled chromosomal DNA from E. coli was isolated from late-log-phase UT481 cells by phenol extraction and ethanol precipitation essentially as described previously (10). [Thymidine-methyl-3H]DNA (derived from E. coli) (NEN-Perkin Elmer, Boston, Mass.) was mixed with unlabeled chromosomal E. coli DNA to provide a substrate with the desired specific radioactivity. The nuclease assay was performed in a 20-µl volume, with 2.4 µg of [3H]DNA as the substrate (360 µM nucleotides). UL12 (6.75 ng; 5 nM) and UL12.5 (5.5 ng; 5 nM) were assayed for nuclease activity using the following buffer: 20 mM Tris-Cl, pH 8.8, 40 mM NaCl, 10 mM MgCl2, 1 mM DTT. Reaction mixtures were incubated at 37°C and then stopped with 5 µl of 0.6-mg/ml DNA and 25 µl of 20% (wt/vol) trichloroacetic acid. After 10 min on ice, samples were centrifuged for 10 min at 14,000 x g, and the radioactivity in 25 µl of the supernatant fraction was determined by scintillation counting.
Endonuclease assay. UL12 or UL12.5 (200 nM) was incubated at 37°C in a 20-µl reaction volume with 225 ng of pEGFP-C1 plasmid in a buffer consisting of 20 mM Tris-Cl, pH 8.8, 40 mM NaCl, 10 mM MgCl2, and 1 mM DTT. The reaction was stopped by adding 5 µl of 5x stop buffer. Samples were electrophoresed on a 1% agarose gel with 0.7 µg of ethidium bromide/ml in TAE buffer.
IF microscopy. Vero cells were plated on glass coverslips and transfected as described above. When indicated, the cells were superinfected with AN-1 virus (at a multiplicity of infection of 5) at 24 h posttransfection. At 24 h posttransfection, or 5 h postsuperinfection, the cells were processed for immunofluorescence (IF) microscopy. After a brief wash with PBS, the cells were fixed by incubating them with 4% (wt/vol) paraformaldehyde in PBS for 10 min at room temperature. The cells were then washed with PBS and permeabilized for 10 min in 1% Triton X-100 in PBS. Coverslips were blocked in 3% normal goat serum (NGS) in PBS overnight at 4°C and then incubated with primary antibody diluted in 3% NGS for 1.5 h at room temperature. For the detection of UL12 and UL12.5, the anti-UL12 antibody BWp12 was used (3, 24). For the detection of proteins with an HA tag, the anti-HA antibody sc-805 (Santa Cruz Biotechnology) was used. After extensive washing with PBS, cells were incubated for 1.5 h with Alexa Fluor 488 goat anti-rabbit secondary antibody (Molecular Probes) in 3% NGS. After a final wash in PBS, the coverslips were mounted in glycerol gelatin containing 2.5% 1,4-diazobicyclo-[2.2.2]octane to retard photobleaching. For the detection of GFP fusion proteins, cells were fixed in paraformaldehyde, washed with PBS, and mounted on slides as described above. The coverslips were mounted on slides and observed under oil immersion. A BX60 microscope (Olympus America Inc., Melville, N.Y.) was used for the visualization of samples.
Complementation assay. Vero cells were plated in 35-mm-diameter dishes and transfected as described above. Twenty-four hours posttransfection, the cells were superinfected with the AN-1 virus at a multiplicity of infection of 5 and incubated for 1 h. The cells were then washed five times with PBS, and 2 ml of fresh medium was added. Eighteen hours later, the medium was collected and titers were determined by a plaque assay of the permissive cell line 6-5.
|
|
|---|
The UL12.5 gene was integrated into the baculovirus genome using the Bac-to-Bac system and was expressed from the polyhedrin promoter. In order to improve translation of the transcript, the sequence directly upstream of the first ATG in UL12.5 was changed to GCCACC, in accordance with the Kozak consensus sequences (19). Sf9 cells were infected with the recombinant baculovirus, and the UL12.5 protein was expressed, appearing as a 55-kDa band on SDS-PAGE (Fig. 1A, lanes 2 to 5). The amount of UL12.5 protein increased with the amount of baculovirus stock used to infect the insect cells. UL12 protein expressed in AcAN-infected cells was also clearly detectable (Fig. 1A, lanes 6 to 9). To determine whether the protein expressed was soluble, the extracts were centrifuged at 100,000 x g, and the supernatants were again analyzed by SDS-PAGE. Like UL12, which had been previously demonstrated to be soluble in this system, UL12.5 appears soluble by this analysis (Fig. 1B, lanes 2 to 5). The UL12.5 protein was purified from the baculovirus-infected insect cells and was estimated to be >90% pure by densitometry of Coomassie blue-stained gels (Fig. 1C). The identity of the UL12.5 protein was confirmed by immunoblot analysis using the anti-UL12 antibody BWp12 that also recognizes UL12.5 (24) (data not shown). The UL12 and UL12.5 proteins appear as doublets (Fig. 1C). This characteristic has been noted before for these proteins and may be due to posttranslational modification (4, 16).
![]() View larger version (40K): [in a new window] |
FIG. 1. Expression and purification of UL12.5. SF21 cells were infected with increasing amounts of AcAN (for UL12) or AcUL12.5 (for UL12.5) baculovirus stock. (A and B) Total (A) and soluble-fraction (B) cell lysates were subjected to SDS-PAGE, and the gels were stained by Coomassie brilliant blue. (C) Purified UL12 and UL12.5. Masses are expressed in kilodaltons (kDa).
|
The exonuclease activities of the proteins were assayed on a substrate consisting of total E. coli chromosomal DNA. As shown in Fig. 2, both UL12 and UL12.5 possess nuclease activity, but UL12.5 appears to be slightly less active and the activity reaches a plateau quickly. This is in contrast to UL12, where the activity remains linear for at least 15 min. Thus, it appears that UL.12.5 retains significant nuclease activity. Although it is formally possible that a portion of the nuclease activity exhibited by UL12.5 is due to the presence of a contaminating nuclease in the preparation, we think it is unlikely that this contaminating nuclease contributes significantly to the activities seen. The UL12 and UL12.5 proteins are purified to >90% purity, indicating that any contaminant would have to have very high specific activity to account for the results seen in Fig. 2. Moreover, the observation that UL12.5 exhibits exonuclease activity is consistent with the results of previous studies with purified proteins (4, 11).
![]() View larger version (16K): [in a new window] |
FIG. 2. Exonuclease activity of UL12.5. Exonuclease activity was measured using 2.4 µg of 3H-labeled E. coli DNA (360 µM nucleotides) and 5 nM UL12 or UL12.5 as described in Materials and Methods. Open circles, UL12; solid squares, UL12.5.
|
![]() View larger version (26K): [in a new window] |
FIG. 3. Endonuclease activity of UL12.5. pEGFP-C1 plasmid (100 ng) was incubated with 100 pmol of UL12.5 or UL12 protein for the times indicated, as described in Materials and Methods. The samples were run on a 0.7% agarose gel in TAE buffer and stained with ethidium bromide. C, control (no protein added).
|
The interaction between UL12.5 (or UL12) and ICP8 was analyzed by coimmunoprecipitation. Immunoprecipitations were carried out using lysates of insect cells infected with recombinant baculoviruses, either alone or in combination. Figure 4 shows that the soluble fractions of the lysates expressed similar amounts of UL12 and UL12.5, as detected by Western blotting with the anti-UL12 antibody (Fig. 4A). Likewise, cells expressing ICP8 either alone or in combination with UL12 or UL12.5 contained equal amounts of this protein (Fig. 4C). For the immunoprecipitation, the monoclonal anti-ICP8 antibody was used, and the potential interaction partners, UL12.5 and UL12, were detected by Western blot analysis of the precipitated proteins. Both UL12.5 and UL12 were coimmunoprecipitated with ICP8 (Fig. 4B, lanes 5 and 6, respectively), indicating that both UL12.5 and UL12 interact with ICP8. Figure 4D is a control showing that the same amount of ICP8 was immunoprecipitated in each lane. Therefore, the inability of UL12.5 to complement the UL12 null mutant is not due to an inability of UL12.5 to interact with ICP8. Furthermore, this experiment shows that the UL12-ICP8 interaction domain is not found in the first 126 amino acids of UL12.
![]() View larger version (23K): [in a new window] |
FIG. 4. Coimmunoprecipitation of UL12, UL12.5, and ICP8. UL12, UL12.5, and ICP8 were expressed in Sf21 insect cells through infection with recombinant baculoviruses. The anti-ICP8 antibody 39-S was used for immunoprecipitation of proteins from soluble cell lysates. Protein A-G agarose was used to bind the antibody-protein complexes. Soluble cell lysates (A and C) and anti-ICP8 immunoprecipitates (B and D) were separated by SDS-PAGE, blotted to nitrocellulose, and probed with anti-UL12 Bwp12 antibody (A and B) or with anti-ICP8 antibody 3-83 (C and D). Lanes 1, mock infection; lanes 2, infection with AcUL12.5; lanes 3, infection with AcAN; lanes 4, infection with AcUL29; lanes 5, infection with AcUL29 and AcUL12.5; lanes 6, infection with AcUL29 and AcAN. +, present; , absent.
|
![]() View larger version (23K): [in a new window] |
FIG. 5. Strand exchange activities of UL12.5 and ICP8. (Left) Schematic representation of the strand exchange reaction. (Right) Strand exchange with UL12, UL12.5, and ICP8. Linear double-stranded and circular single-stranded M13 DNA substrates were incubated with 13.9 nM UL12 or UL12.5 and 1.75 µM ICP8 at 37°C for the times indicated. Samples were run on a 0.7% agarose gel in TAE buffer and stained with ethidium bromide. ds, double-stranded DNA; ss, single-stranded DNA; se, strand exchange products; +, present; , absent.
|
![]() View larger version (20K): [in a new window] |
FIG. 6. Expression of UL12.5 in transfected Vero cells. Vero cells were transfected with the plasmids pSAK, pSAKUL12/12.5HA, pSAKUL12HA, and pSAKUL12.5HA as described in Materials and Methods. The amounts of expressing plasmids used were 5, 40, 200, and 600 ng, although the empty parent vector pSAK was added to each transfection so that each plate was transfected with a total of 1 µg of DNA. Lane 1, control, with transfection of 1 µg of pSAK only. Cells were collected 24 h posttransfection, and extracts were analyzed by SDS-PAGE. Proteins were immunoblotted, and the anti-HA antibody sc-805 was used for detection. Numbers on left refer to kilodaltons.
|
![]() View larger version (18K): [in a new window] |
FIG. 7. Complementation of the AN-1 mutant virus by transfection with UL12-expressing plasmids. Vero cells were transfected with the plasmids pSAK, pSAKUL12, pSAKUL12/12.5, pSAKUL12.5, pSAKUL12HA, pSAKUL12/12.5HA, and pSAKUL12.5HA and superinfected with the AN-1 virus 24 h posttransfection. Cell supernatants were collected 18 h later, and titers were determined on the complementing cell line 6-5. Relative complementation was calculated by setting the number of plaques obtained with 600 ng of pSAKUL12/12.5 (wild-type) transfection at 100%. Solid bars, 600 ng of plasmid; shaded bars, 40 ng of plasmid; mock, transfected with control plasmid.
|
![]() View larger version (77K): [in a new window] |
FIG. 8. UL12 localizes to the nucleus and UL12.5 does not. Vero cells were transfected with 600 ng of plasmids pSAK, pSAKUL12/12.5, pSAKUL12.5, and pSAKN126 for the analysis of mock, wild-type UL12, UL12.5, and the N terminus of UL12, respectively. In the panels on the left, cells were fixed and processed for IF 24 h posttransfection. In the panels on the right, cells were superinfected with AN-1 virus 24 h posttransfection and then fixed and processed 5 h postinfection. The anti-UL12 antibody Bwp12 was used as the primary antibody, and Alexa Fluor 488-conjugated goat-anti-rabbit was used as the secondary antibody. Bar, 40 µm.
|
![]() View larger version (35K): [in a new window] |
FIG. 9. Localization of GFP fusion proteins. Vero cells were transfected with 600 ng of the plasmid pEGFP-C1 (a) or pSAKN126-GFP (b) for the expression of EGFP and the UL12-N terminus-EGFP fusion protein, respectively. The cells were fixed 24 h posttransfection. Bar, 50 µm.
|
|
|
|---|
Proline-rich domains are found in many sites of protein-protein interaction (15). The N terminus of UL12 is rich in prolines, and this suggested that the problem with UL12.5 was that it was unable to contact a protein important for its in vivo activity. Of special interest was the HSV-1 single-stranded DNA binding protein, ICP8, which had been shown to interact with UL12 (34, 36). Thomas et al. have mapped domains of ICP8 responsible for interaction with UL12. These include the region of amino acids 325 to 585, as well as the C-terminal 167 residues (34). However, the corresponding regions of UL12 responsible for interaction with ICP8 have not yet been mapped. Our study shows that the ICP8 interaction domain of UL12 is not located within the first 126 amino acids of UL12. It will be interesting to see if a mutant of UL12 can be found that is nuclease active but unable to interact with ICP8 and whether such a mutant would be able to mediate strand exchange and complement AN-1.
Although the exact in vivo role of UL12 has not yet been defined, all of the suggested possibilities for UL12 activity, from processing of replicated DNA for packaging into capsids (37) to a role in recombination associated with replication (26), take place in the nucleus. Therefore, it is expected that UL12 would need to localize to the nucleus. Thomas et al. found that UL12 localized to the nucleus even in cells infected with viruses encoding mutant forms of ICP8 which did not localize to the nucleus, implying that UL12 possesses its own NLS (34). Kehm et al. also demonstrated that UL12 and a C-terminal 123-amino-acid truncated form of UL12 both localized to the nucleus in the absence of any other herpesvirus protein (16). Here, we confirm that UL12 does possess its own NLS and that it is contained within the N-terminal 126 residues of UL12. The NLS is most likely to be amino acids 35 to 39 (KRPRP), which was identified as an NLS by the PredictNLS program (5). The EBNA-2 protein from Epstein-Barr virus and mouse polyomavirus T antigen also possess identical sequences, which have been experimentally confirmed to be functional NLSs (20, 27). Our results demonstrate experimentally that the N terminus of UL12 contains an effective NLS, as fusion of this region to GFP, which normally is distributed over the entire cell, caused GFP to localize strictly to the nucleus. The UL12.5 protein, which lacks this domain, was found to localize to the cytoplasm.
These results do not explain why HSV-1 has evolutionarily retained the ability to transcribe a subgenic version of UL12. We do know that it is not essential for viral growth in culture (22). As has been suggested previously (22), it may be required for growth in animals or for latency or it may represent an earlier version on the evolutionary path to full-length UL12. Further work will be necessary to investigate these possibilities.
Our results reveal several factors that contribute to the inability of UL12.5 to complement the UL12 null virus, AN-1. The nuclease activity of the UL12.5 protein was lower than that of UL12, possibly due to lower stability of the UL12.5 protein. The UL12.5 protein was less soluble than UL12 and tended to aggregate in vivo, lowering its effective concentration in the cell. Furthermore, in previous studies, when complementation was studied using constructs and viruses employing the natural promoter of UL12.5, the total amount of UL12.5 expressed was much smaller than that of UL12 (24). Since the natural promoter of UL12.5 provides threefold less expression of UL12.5 than UL12 (7), this probably explains our previous failure to observe complementation of AN-1 by UL12.5. These various factors all contribute to the deficiency of UL12.5. However, we find it significant that the NLS resides in the N terminus of UL12, which is not found in the N-terminally truncated UL12.5. The localization of UL12.5 in the cytoplasm, prevented by the nuclear boundary from taking part in HSV-1 replication, would logically be primarily responsible for its inability to complement AN-1.
This work was supported by the Cancer Research Fund of the Damon Runyon-Walter Winchell Foundation Fellowship, DRG-1625 (N.B.R.), and Public Health Service grants AI21747 and AI37549 (S.K.W.).
N.B.R. and S.A. contributed equally to this work. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»